• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Almac, TTP Labtech form alliance in fluorescence lifetime technology

Almac, TTP Labtech form alliance in fluorescence lifetime technology

January 7, 2013
CenterWatch Staff

Global service provider Almac and TTP Labtech, a global developer and manufacturer of laboratory equipment, have formed an alliance in the field of fluorescence lifetime (FLT) technology to provide class leading screening performance. This will give customers of either party access to a broad range of biological applications coupled with the next generation of microplate reader technology.

FLT as a reading modality offers a robust, antibody-free, homogeneous assay platform which enables the user to avoid interference from fluorescent compounds within a screening library. Developed utilizing experience in peptide engineering and chemical synthesis and design, Almac’s Flexyte assays harness the power and potential of FLT to provide an efficient and economical platform for screening and profiling. The evolving assay platform offers solutions for many major therapeutic target classes including kinases, proteases, phosphatases, DUB and an increasing number of epigenetic targets.

TTP Labtech’s Ameon system represents the next generation of FLT reader technology. By offering real-time decay curve analysis, the Ameon system provides a revolutionary combination of speed, precision and data quality for FLT assays that can be readily integrated into HTS workflows.

‘The development of the Ameon reader by TTP Labtech has introduced an exciting new dimension to FLT technology and we are pleased that Almac’s Flexyte customers will be able to benefit from this advance in reader technology’ said Dr Stephen Barr, president and managing director of Almac Sciences.

Dr. Wayne Bowen, CSO of TTP Labtech, added, “We are excited by the potential of the Flexyte and Ameon reader combination to deliver robust, cost-effective screening results and enhanced productivity through better discrimination of lead compounds.”

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing